The Lancet: Results of Phase 2b Trial of Novel TB Regimen PaMZ Show Potential to Shorten, Improve TB Treatment
A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard
News
Press Releases
Global Phase 3 “STAND” Trial Launched to Test New Tuberculosis Drug Regimen PaMZ to Shorten, Improve Treatment
* STAND trial will take place in approximately 50 study sites in Africa, Asia, Caribbean, Eastern Europe, and Latin America
News
TB Alliance Advances Next-generation TB Drug Candidate into Clinical Testing
TB Alliance has announced the start of the first human trial of a new tuberculosis (TB) drug candidate, designated TBA-354.
News
Phase 2a Published Results Show the Potential of a New TB Regimen with Novel Drugs Bedaquiline and Pretomanid (PA-824)
A promising new tuberculosis (TB) drug regimen, which could improve the treatment of drug sensitive TB and multi-drug resistant (MDR-)
News
TB Alliance Announces Two New Members to Its Board of Directors: Dr. Mario Raviglione of WHO and Shalini Sharp of Ultragenyx
TB Alliance, an international not-for-profit organization with the mission of developing improved tuberculosis (TB) treatments, announced the appointment of Mario
News
Developing New Tuberculosis Drugs from Marine Natural Products: Joint research program between OPBIO and TB Alliance announced
OPBIO Factory Co., Ltd. (OPBIO) has signed a research agreement with the Global Alliance for TB Drug Development (TB Alliance).
News
TB Alliance Launches Phase 2B Clinical Trial of a Novel TB Drug Regimen that Could Cut Treatment Time by Half or More for a Majority of TB Patients
TB Alliance has launched a Phase 2B trial that will test the safety and effectiveness of a novel regimen with
News
PA-824 has a New Generic Name: Pretomanid
TB Alliance announced today that pretomanid (pronounced: pree TOH mah nid) will be the generic, nonproprietary name for its novel
News
Results of Phase 3 Clinical Trial of New Tuberculosis Drug Regimen Published in New England Journal of Medicine
· REMoxTB confirmed the safety of moxifloxacin and its effect in killing TB; results pave way for further study of
News
Novartis Provides Drug Candidate Compounds to TB Alliance
Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development (TB Alliance) for compounds